You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CXCR1/2 (chemokine receptor)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Thymoma Trial in Beijing (68Ga-Pentixafor)

Recruiting
  • Thymoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospitall, Chinese Academy of Medic
Oct 11, 2023

Aldosterone-Producing Adenoma Trial in Chengdu ([18F]AlF-NOTA-pentixather PET/CT)

Recruiting
  • Aldosterone-Producing Adenoma
  • [18F]AlF-NOTA-pentixather PET/CT
  • Chengdu, Sichuan, China
    Sichuan Academy of Medical Sciences.Sichuan Provincial People's
Apr 3, 2023

Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma Trial in New York, Providence (Motixafortide, Cemiplimab,

Recruiting
  • Pancreatic Cancer
  • +2 more
  • New York, New York
  • +1 more
Nov 7, 2022

Lymphoma, Multiple Myeloma, Leukemia Trial in Fuzhou (68Ga-Pentixafor)

Recruiting
  • Lymphoma
  • +2 more
  • Fuzhou, Fujian, China
    Department of Nuclear Medicine, First Affiliated Hospital of Fuj
Apr 6, 2021

Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative Trial in Buffalo (procedure, drug, biological)

Active, not recruiting
  • Triple -Negative Breast Cancer
  • +4 more
  • Biopsy
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Aug 1, 2022

COVID-19, SARS-CoV2 Infection Trial in India (Candesartan Cilexetil, Repagermanium, Candesartan Placebo)

Recruiting
  • COVID-19
  • SARS-CoV2 Infection
  • Candesartan Cilexetil
  • +3 more
  • Guntur, India
  • +4 more
Mar 13, 2022

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston

Active, not recruiting
  • Metastatic Melanoma
  • +2 more
  • Aldesleukin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Glucagon-like Peptide-1 Receptor Agonists According to Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Bari, Italy
    Azienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023

Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial in

Suspended
  • Anatomic Stage 0 Breast Cancer AJCC v8
  • +18 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 4, 2022

Glioblastoma Trial in Gainesville (Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells)

Not yet recruiting
  • Glioblastoma
  • Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
  • Gainesville, Florida
    University of Florida Health
Jul 29, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Diabetes Trial in Nanjing (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc)

Recruiting
  • Diabetes
  • Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
  • Nanjing, China
    Nanjing First Hospital, Nanjing Medical Univesity
Aug 6, 2023

Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)

Active, not recruiting
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jun 20, 2022

Type 2 Diabetes Trial in Lancaster (Exenatide Injection, Saline injection)

Terminated
  • Type 2 Diabetes
  • Exenatide Injection
  • Saline injection
  • Lancaster, Pennsylvania
    Amish Research Clinic
Mar 6, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +3 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 9, 2023

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine

Not yet recruiting
  • Digestive System Neuroendocrine Tumor G1
  • +5 more
  • Tumor Debulking
  • +5 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Aug 23, 2023

Breast Tumors Trial in Chuo Ku, Koto-Ku (H3B-6545, Antihistamine)

Active, not recruiting
  • Breast Neoplasms
  • Chuo Ku, Japan
  • +1 more
Dec 19, 2022

Glucagon-like Peptide 1 Receptor Agonists and Mental Health

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • GLP-1 receptor agonist
  • (no location specified)
Aug 4, 2022

Osteoporosis, Postmenopausal, Diabetes, Type 2 Trial in Jackson (GLP-1 receptor agonist)

Recruiting
  • Osteoporosis, Postmenopausal
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Jackson, Mississippi
    University of Mississippi Medical Center
Aug 5, 2022

Therapeutic Drug Use for CKD Patients

Active, not recruiting
  • Chronic Kidney Disease
  • angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
  • Jinan, Shandong, China
    Xiao Li，MD
Apr 18, 2023

Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

Recruiting
  • Breast Cancer
  • Saint Louis, Missouri
  • +2 more
Jan 12, 2023

Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

Not yet recruiting
  • Neuroendocrine Tumor (NET)
  • Colorectal Cancer (CRC)
  • CHM-2101 CAR-T cells
  • (no location specified)
Sep 20, 2023

Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

Recruiting
  • Early-stage Breast Cancer
  • +4 more
  • Trastuzumab and nelatinib
  • Trastuzumab and Parstuzumab
  • Guangzhou, China
    Sun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023